CD8A and neoplasm: MIS416 Vax followed by MRB-OVA boosting led to significant expansion of OVA-specific CD8+ T cells compared to vaccination alone (Fig. 2a), which persisted at high frequency in circulation (Additional file 2: Figure S1b), and significantly improved survival of tumor-bearing mice (Fig. 2b).